Literature DB >> 11174848

Mechanisms in the skeletal complications of breast cancer.

T J Martin1, J M Moseley.   

Abstract

Breast cancer is the most common malignancy in women, with a worldwide prevalence of 1.5 million throughout the industrialized countries. Its mortality rate is second only to lung cancer in the USA and Europe. Its high incidence and prevalence makes it a major public health problem. Up to one-third of women with early stage breast cancer will eventually succumb to the disease, and most of these will develop bone metastases during the course of the disease. Approximately 70% of patients with breast cancer have bone metastases, with 27% having lung and liver metastases. Hypercalcemia also is very common in advanced breast cancer, manifesting itself in one-third of patients late in the disease. Breast cancer accounts for approximately 25% of the cases of hypercalcemia in cancer. The major skeletal complications of breast cancer--hypercalcemia and bone metastases--almost certainly share certain mechanisms and these will be discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11174848     DOI: 10.1677/erc.0.0070271

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  18 in total

1.  Both cell-surface and secreted CSF-1 expressed by tumor cells metastatic to bone can contribute to osteoclast activation.

Authors:  Kader Yagiz; Susan R Rittling
Journal:  Exp Cell Res       Date:  2009-05-08       Impact factor: 3.905

2.  Ex-vivo analysis of the bone microenvironment in bone metastatic breast cancer.

Authors:  Karen M Bussard; Andrea M Mastro
Journal:  J Mammary Gland Biol Neoplasia       Date:  2009-12-02       Impact factor: 2.673

3.  The Shoulder Pain due to Metastatic Breast Cancer -A Case Report-.

Authors:  Sae Young Kim; Min Woo Jung; Jin Mo Kim
Journal:  Korean J Pain       Date:  2011-06-07

Review 4.  Current role of bone scan with phosphonates in the follow-up of breast cancer.

Authors:  Lorenzo Maffioli; Luigia Florimonte; Luca Pagani; Ivana Butti; Isabel Roca
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-16       Impact factor: 9.236

5.  Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models.

Authors:  Abhik Bandyopadhyay; Long Wang; Joseph Agyin; Yuping Tang; Shu Lin; I-Tien Yeh; Keya De; Lu-Zhe Sun
Journal:  PLoS One       Date:  2010-04-28       Impact factor: 3.240

6.  The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors.

Authors:  Allan Lipton; Robert Uzzo; Robert J Amato; Georgiana K Ellis; Behrooz Hakimian; G David Roodman; Matthew R Smith
Journal:  J Natl Compr Canc Netw       Date:  2009-10       Impact factor: 11.908

7.  Analysis of clinicopathological factors associated with bone metastasis in breast cancer.

Authors:  Jing Chen; Shu Zhu; Xiu-Zhen Xie; Shan-Feng Guo; Liang-Qian Tong; Sheng Zhou; Ming Zhao; Zhi-Qun Xianyu; Xiao-Hua Zhu; Wei Xiong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-02-08

8.  Transfection of MDA-MB-231 human breast carcinoma cells with bone sialoprotein (BSP) stimulates migration and invasion in vitro and growth of primary and secondary tumors in nude mice.

Authors:  Julie A Sharp; Mark Waltham; Elizabeth D Williams; Michael A Henderson; Erik W Thompson
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

9.  PTHrP Overexpression Increases Sensitivity of Breast Cancer Cells to Apo2L/TRAIL.

Authors:  Vanessa Cheung; Steve Bouralexis; Matthew T Gillespie
Journal:  PLoS One       Date:  2013-06-18       Impact factor: 3.240

10.  Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid.

Authors:  Toni Ibrahim; Laura Mercatali; Emanuele Sacanna; Anna Tesei; Silvia Carloni; Paola Ulivi; Chiara Liverani; Francesco Fabbri; Michele Zanoni; Wainer Zoli; Dino Amadori
Journal:  Cancer Cell Int       Date:  2012-11-22       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.